Chronic kidney disease (CKD) is increasing in prevalence worldwide. The number of end-stage renal disease patients requiring treatment by dialysis is estimated to be increasing by 10,000 patients per year in Japan. Furthermore, it has been estimated that about 13 million people are living with CKD in Japan. Various complications are associated with CKD, including hypertension, hyperlipidemia, anemia, hyperphosphatemia, hyperkalemia, osteodystrophy, and uremia. More than one-third of CKD patients will die from cardiovascular disease (CVD), such as cardiac failure, stroke, and myocardial infarction. Thus, the prevention of CVD is a primary concern for the treatment of CKD patients. Over the past decade, epidemiological studies have clarified various non-traditional risk factors for CVD in CKD patients (1). Hypertension and dyslipidemia are well-known traditional risk factors for CVD, while hyperphosphatemia, anemia and albuminuria are non-traditional CKDrelated CVD risk factors. It is critical to manage these risk factors in CKD patients to prevent CVD.
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Intestinal Phosphate Absorption in CKD Patients
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ing the phosphate absorption of CKD patients is vital to decrease their risk of CVD. Dietary phosphate restriction is a straightforward approach to reduce the intestinal phosphate absorption. However, phosphate is present in most foods, especially animal protein-rich foods and processed foods. It is difficult to achieve a sufficient decrease of phosphate intake by the modification of diet alone, and therefore phosphate binders are widely prescribed to CKD patients. Commercially available phosphate binders for the treatment of hyperphosphatemia include calcium carbonate, sevelamer hydrochloride, lanthanum carbonate, and ferric citrate. However, these phosphate binders have some side effects, including gastrointestinal problems and hypercalcemia. Thus, it would be desirable to develop other inhibitors of intestinal phosphate absorption that work by a different mechanism from that of phosphate binders.
Niacin and Phosphate Metabolism
Nicotinic acid and nicotinamide are converted to nicotinamide adenine dinucleotide (NAD) or NADP, and can act as a coenzyme for numerous enzymatic oxidation-reduction reactions.
In their earlier study, Kempson et al. demonstrated that NAD can inhibit sodium-dependent phosphate transport activity at the renal brush border membrane (4). Recently, Nomura et al. reported that increased nicotinamide and nicotinamide phosphoribosyltransferase (Nampt) after partial hepatectomy of rats suppressed the expression levels of both renal and intestinal sodium-dependent phosphate transporters, resulting in hypophosphatemia (5) . Nicotinamide is a metabolite of NAD; however, nicotinamide can also be re-converted to NAD by Nampt. Inhibition of Nampt by the specific inhibitor FK866 increased the serum phosphate level and renal phosphate reabsorption.
Nicotinamide has also been identified as an inhibitor of intestinal phosphate absorption. We previously reported that nicotinamide inhibited sodium-dependent phosphate cotransport activity in the rat small intestine (6) . There are three types of sodium-dependent phosphate transporter in mammals, type I (NaPi-I), type II (NaPi-IIa, NaPi-IIb, NaPi-IIc), and type III (PiT-1, PiT-2). NaPi-IIb has been identified as a major sodiumdependent phosphate transporter in the brush border membrane of the mammalian small intestine. Eto et al. clearly demonstrated that nicotinamide inhibited intestinal sodium-dependent phosphate transport in adenineinduced CKD rats by decreasing NaPi-IIb expression in the intestinal brush border membrane (7) . Therefore, NAD metabolism plays an important role in intestinal and renal phosphate handling, and presents a possible target for the treatment of hyperphosphatemia in CKD patients.
Effects of Niacin on Hyperphosphatemia in CKD Patients
Niacin and related compounds have been utilized as drugs to treat hypertriglyceridemia with a low high-density lipoprotein (HDL) cholesterol level. Various niacin derivatives such as esterified nicotinamide, and prodrug or extended-released formulation of nicotinic acid, have been developed and prescribed to dyslipidemic patients.
Niceritrol, which is a prodrug of nicotinic acid, or nicotinamide can suppress hyperphosphatemia in hemodialysis patients (8, 9) . Takahashi et al. treated 65 Japanese hemodialysis patients with nicotinamide for 12 wk (9) . Administration of nicotinamide (the mean dose was 1,080 mg/d) significantly decreased serum phosphate from 6.961.5 mg/dL to 5.461.3 mg/dL, increased blood NAD from 9.361.9 nmol/10 5 erythrocytes to 13.265.3 nmol/10 5 erythrocytes, and increased serum HDL-cholesterol from 47.4614.9 mg/ dL to 67.2622.3 mg/dL. Rennick et al. reviewed the published studies that had evaluated the role of niacin or nicotinamide in decreasing serum phosphate levels in dialysis patients (10) . Six of the seven studies included in the review reported that niacin or nicotinamide significantly decreased the serum phosphate level.
Future Perspectives and Conclusion
Hyperphosphatemia and dyslipidemia are critical but modifiable risk factors for CVD in CKD patients. In addition, findings suggest that niacin can suppress the progression of CKD in an experimental rat model (11) . Thus, niacin and related compounds are likely to be beneficial for CKD patients. Various effective medicines are available for the treatment of hyperphosphatemia and dyslipidemia. However, increases in the number of medicines prescribed may cause poor compliance with medication, potentially worsening the disease, and also an increased treatment cost. Niacin and related compounds can be effective for the treatment of both hyperphosphatemia and dyslipidemia. In addition, they are cheap and effective, requiring only one or two tablets per day to control serum phosphate and HDL-cholesterol levels. Therefore, niacin and related compounds may provide affordable treatment for CKD patients with better compliance.
On the other hand, side-effects of these compounds must be considered. Flushing is a well-recognized side effect of niacin. Additionally, headache, itching, burning, sweating, chills dizziness, stomach upset, vomiting, and diarrhea may also occur. The long-term safety of niacin and related compounds for CKD patients has not been evaluated. Thus, large-scale multicenter studies should be performed to address the appropriate dose, long-term safety and efficacy to achieve optimal control of hyperphosphatemia and dyslipidemia in CKD patients.
